Nanobiotix’s Post

We’re thrilled to announce that the first patient has been dosed in the Phase 2 CONVERGE study! This randomized trial evaluates groundbreaking nanotherapeutic candidate JNJ-1900 (NBTXR3) for patients with stage 3, unresectable non-small cell lung cancer. This achievement brings us one step closer to transforming cancer treatment and expanding possibilities for millions of patients worldwide. #Nanobiotix #CancerCareInnovation #Radiotherapy #Biotech #JNJ1900

Excited to share my contribution to a study on the potential of vincamine-loaded silver nanoparticles (VCN-AgNPs) as a new therapeutic approach against Ehrlich's solid carcinoma. This research highlights the powerful anticancer effects of VCN-AgNPs, showing remarkable tumor reduction, improved survival rates, and enhanced apoptosis in cancer cells. A promising step forward in cancer treatment! #CancerResearch #Nanomedicine #Innovation #TherapeuticAdvances #EhrlichCarcinoma https://lnkd.in/euU3sKf8

Exploring the intricate signaling pathways in colorectal cancer: Implications for targeted therapies. This comprehensive review provides a valuable resource for understanding the complexities of Colorectal cancer (CRC) signaling pathways, guiding the development of effective targeted therapies. Continued research, focusing on overcoming resistance, optimizing drug combinations, and utilizing innovative models like colonic organoids, holds the key to improving patient outcomes in the fight against CRC. https://hubs.ly/Q02D18lw0

According to preliminary data presented at #ESMO24, an antitumour activity of telisotuzumab adizutecan (ABBV-400), a c-Met directed antibody-drug conjugate (ADC), was observed in previously treated patients with EGFR wild type (WT) non-squamous non-small cell lung cancer (#NSCLC). To learn more about this topic, read the #ESMODailyReporter article 📌https://ow.ly/vV3J50TCVvR

Some breast cancer patients with low levels of the protein HER2 could benefit from next-generation antibody drug conjugate (ADC) targeted therapy—but how can we effectively identify these patients? That’s what makes Danaher’s recent Beacon collaboration with Yale University, the University of Pennsylvania and the Translational Breast Cancer Research Consortium (TBCRC) so exciting: The initiative will use technology from our sister companies Leica Biosystems and Cepheid to work towards improving precision diagnostics for breast cancer patients expressing low levels of HER2. https://lnkd.in/e_nPySg4

Some breast cancer patients with low levels of the protein HER2 could benefit from next-generation antibody drug conjugate (ADC) targeted therapy—but how can we effectively identify these patients? That’s what makes Danaher’s recent Beacon collaboration with Yale University, the University of Pennsylvania and the Translational Breast Cancer Research Consortium (TBCRC) so exciting: The initiative will use technology from our sister companies Leica Biosystems and Cepheid to work towards improving precision diagnostics for breast cancer patients expressing low levels of HER2. https://lnkd.in/e2A5Z-Hq

Gnubiotics Sciences SA, we’re exploring how glycan-programmed T cells can potentially improve outcomes for colorectal cancer patients. Our upcoming poster presentation at ESMO 2024 will highlight: ✅ How glycan modifications enhance T cell activation and targeting. ✅ Preclinical results demonstrating improved tumor suppression. ✅ Potential implications for personalized cancer treatments. We’re excited to contribute to the evolving landscape of oncology and look forward to engaging discussions at the conference. Mark your calendars for September 15th! 🗓️ #CancerInnovation #ESMO2024 #Immunotherapy #Gnubiotics #GlycanScience

Some breast cancer patients with low levels of the protein HER2 could benefit from next-generation antibody drug conjugate (ADC) targeted therapy—but how can we effectively identify these patients? That’s what makes Danaher’s recent Beacon collaboration with Yale University, the University of Pennsylvania and the Translational Breast Cancer Research Consortium (TBCRC) so exciting: The initiative will use technology from our sister companies Leica Biosystems and Cepheid to work towards improving precision diagnostics for breast cancer patients expressing low levels of HER2. https://lnkd.in/eANAtSa3

Some breast cancer patients with low levels of the protein HER2 could benefit from next-generation antibody drug conjugate (ADC) targeted therapy—but how can we effectively identify these patients? That’s what makes Danaher’s recent Beacon collaboration with Yale University, the University of Pennsylvania and the Translational Breast Cancer Research Consortium (TBCRC) so exciting: The initiative will use technology from our sister companies Leica Biosystems and Cepheid to work towards improving precision diagnostics for breast cancer patients expressing low levels of HER2. https://lnkd.in/eW5B84vD

Some breast cancer patients with low levels of the protein HER2 could benefit from next-generation antibody drug conjugate (ADC) targeted therapy—but how can we effectively identify these patients? That’s what makes Danaher’s recent Beacon collaboration with Yale University, the University of Pennsylvania and the Translational Breast Cancer Research Consortium (TBCRC) so exciting: The initiative will use technology from our sister companies Leica Biosystems and Cepheid to work towards improving precision diagnostics for breast cancer patients expressing low levels of HER2. https://lnkd.in/evpBDeas